Sanofi (SNYNF, SNY) and SK bioscience have entered an expanded agreement to develop, license and commercialize next-generation ...

Sanofi is handing SK bioscience 50 million euros ($52 million) as the longtime partners take their next-gen pneumococcal ...

Given the breadth in immune responses demonstrated by monovalent JN.1 lineage vaccines against circulating variants, the TAG-CO-VAC advises retaining the current COVID-19 vaccine antigen ...

Wellness influencers showed higher rates of vaccine opposition on social media compared to other users’ accounts, according to a new University of Michigan study. New work by U-M School of ...

According to the investigators of a newly published study on the waning of pneumococcal vaccines responses in people with inflammatory arthritis, pneumonia is a major cause of mortality in this ...

Sanofi has moved ahead with plans to challenge Pfizer and MSD for a piece of the market for pneumococcal vaccines, taking a 21-valent shot licensed from SK Biosciences into phase 3 testing.

Sanofi and SK bioscience have entered into a new chapter of their collaboration in pneumococcal vaccines with an expanded agreement to develop, license and commercialize next-generation PCVs for both ...

This week, he’s doing interviews as the film opens in South American markets, but he took time out to weigh in on a movement gaining traction, to limit vaccines as Donald Trump prepares to ...

SV40 is a virus originally found in monkeys. It was used in early polio vaccines that were made using monkey kidney cells. However, SV40 was removed from vaccines many years ago after scientists ...

SK bioscience and Sanofi have expanded their agreement to jointly develop pneumococcal conjugate vaccines (PCVs) targeting both paediatric and adult populations. This partnership extension ...